FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2197626501> ?p ?o ?g. }

• W2197626501 endingPage "43" @default.
• W2197626501 startingPage "27" @default.
• W2197626501 abstract "Although T lymphocytes are widely recognized as important effector cells in the immunopathogenesis of rheumatoid arthritis (RA), therapies targeting T cell populations have not been clinically successful, largely due to the toxicity associated with nonspecific T cell depletion. An alternative approach involves targeting T cell activation, a process that requires two distinct signals. In addition to the cognate interaction between the T cell receptor on T cells and antigen bound to the major histocompatibility complex on the antigen-presenting cell (APC), a second, co-stimulatory, signal is required for T cell activation. Therapies targeting co-stimulatory pathways, aimed at modifying the activation of T cells, rather than reducing their absolute numbers, may be an effective alternative to T cell depletion in RA and other rheumatic diseases. One such treatment, abatacept (CTLA4Ig), a fusion protein combining cytotoxic T lymphocyte antigen 4 (CTLA4) and a portion of the Fc domain of human IgG1, has been approved in the United States and the European Union for the treatment of RA. Abatacept may modulate the T cell or the APC to produce several different outcomes within the joint, including down-regulation of T cell activation, stimulation of T cell apoptosis, or possibly modulation of T regulatory cell activity. In large, controlled trials in patients with RA with an inadequate response to either methotrexate or TNF antagonists, abatacept effectively reduced disease activity. In the methotrexate-inadequate responder population, radiographic progression was slowed when compared to continued treatment with methotrexate alone. The safety profile of this therapy is similar to that of other biological response modifiers, with infection being the most concerning treatment-emergent adverse event. Additional co-stimulatory pathways may offer attractive targets in RA and other immune-mediated diseases, although, to date, none has had the clinical success of abatacept and the related CTLA4Ig fusion protein, belatacept." @default.
• W2197626501 created "2016-06-24" @default.
• W2197626501 creator A5048999112 @default.
• W2197626501 creator A5062155931 @default.
• W2197626501 date "2009-01-01" @default.
• W2197626501 modified "2023-09-26" @default.
• W2197626501 title "Co-stimulatory pathways in the therapy of rheumatoid arthritis" @default.
• W2197626501 cites W1602277155 @default.
• W2197626501 cites W1628992377 @default.
• W2197626501 cites W1945743078 @default.
• W2197626501 cites W1971422121 @default.
• W2197626501 cites W1976375369 @default.
• W2197626501 cites W1978683506 @default.
• W2197626501 cites W1978907635 @default.
• W2197626501 cites W1984049620 @default.
• W2197626501 cites W1996279862 @default.
• W2197626501 cites W2009154052 @default.
• W2197626501 cites W2014081699 @default.
• W2197626501 cites W2029140584 @default.
• W2197626501 cites W2029458048 @default.
• W2197626501 cites W2029957805 @default.
• W2197626501 cites W2037920661 @default.
• W2197626501 cites W2039207296 @default.
• W2197626501 cites W2040017420 @default.
• W2197626501 cites W2046146126 @default.
• W2197626501 cites W2079359234 @default.
• W2197626501 cites W2085476131 @default.
• W2197626501 cites W2092713406 @default.
• W2197626501 cites W2093383759 @default.
• W2197626501 cites W2096430354 @default.
• W2197626501 cites W2097057955 @default.
• W2197626501 cites W2097341637 @default.
• W2197626501 cites W2097811455 @default.
• W2197626501 cites W2100974168 @default.
• W2197626501 cites W2102857621 @default.
• W2197626501 cites W2103972158 @default.
• W2197626501 cites W2107346812 @default.
• W2197626501 cites W2107381832 @default.
• W2197626501 cites W2107690729 @default.
• W2197626501 cites W2114329158 @default.
• W2197626501 cites W2118268169 @default.
• W2197626501 cites W2119014335 @default.
• W2197626501 cites W2124670599 @default.
• W2197626501 cites W2136129817 @default.
• W2197626501 cites W2138049450 @default.
• W2197626501 cites W2141989396 @default.
• W2197626501 cites W2156835571 @default.
• W2197626501 cites W2164903177 @default.
• W2197626501 cites W4244453275 @default.
• W2197626501 doi "https://doi.org/10.1007/978-3-7643-8238-4_2" @default.
• W2197626501 hasPublicationYear "2009" @default.
• W2197626501 type Work @default.
• W2197626501 sameAs 2197626501 @default.
• W2197626501 citedByCount "1" @default.
• W2197626501 crossrefType "book-chapter" @default.
• W2197626501 hasAuthorship W2197626501A5048999112 @default.
• W2197626501 hasAuthorship W2197626501A5062155931 @default.
• W2197626501 hasConcept C147483822 @default.
• W2197626501 hasConcept C1491633281 @default.
• W2197626501 hasConcept C154317977 @default.
• W2197626501 hasConcept C159654299 @default.
• W2197626501 hasConcept C19317047 @default.
• W2197626501 hasConcept C202751555 @default.
• W2197626501 hasConcept C203014093 @default.
• W2197626501 hasConcept C207936829 @default.
• W2197626501 hasConcept C2776090121 @default.
• W2197626501 hasConcept C2777575956 @default.
• W2197626501 hasConcept C2779605438 @default.
• W2197626501 hasConcept C2780653079 @default.
• W2197626501 hasConcept C2908647359 @default.
• W2197626501 hasConcept C502942594 @default.
• W2197626501 hasConcept C55493867 @default.
• W2197626501 hasConcept C71924100 @default.
• W2197626501 hasConcept C86803240 @default.
• W2197626501 hasConcept C8891405 @default.
• W2197626501 hasConcept C98274493 @default.
• W2197626501 hasConcept C99454951 @default.
• W2197626501 hasConceptScore W2197626501C147483822 @default.
• W2197626501 hasConceptScore W2197626501C1491633281 @default.
• W2197626501 hasConceptScore W2197626501C154317977 @default.
• W2197626501 hasConceptScore W2197626501C159654299 @default.
• W2197626501 hasConceptScore W2197626501C19317047 @default.
• W2197626501 hasConceptScore W2197626501C202751555 @default.
• W2197626501 hasConceptScore W2197626501C203014093 @default.
• W2197626501 hasConceptScore W2197626501C207936829 @default.
• W2197626501 hasConceptScore W2197626501C2776090121 @default.
• W2197626501 hasConceptScore W2197626501C2777575956 @default.
• W2197626501 hasConceptScore W2197626501C2779605438 @default.
• W2197626501 hasConceptScore W2197626501C2780653079 @default.
• W2197626501 hasConceptScore W2197626501C2908647359 @default.
• W2197626501 hasConceptScore W2197626501C502942594 @default.
• W2197626501 hasConceptScore W2197626501C55493867 @default.
• W2197626501 hasConceptScore W2197626501C71924100 @default.
• W2197626501 hasConceptScore W2197626501C86803240 @default.
• W2197626501 hasConceptScore W2197626501C8891405 @default.
• W2197626501 hasConceptScore W2197626501C98274493 @default.
• W2197626501 hasConceptScore W2197626501C99454951 @default.
• W2197626501 hasLocation W21976265011 @default.

• next